|AHFS/Drugs.com||Consumer Drug Information|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||240.30 g/mol|
300.3 g/mol (acetate) g·mol−1
|3D model (JSmol)|
|(what is this?)|
Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.
It was patented in 1971 and came into medical use in 1983.
Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.
Mode of action
After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 543. ISBN 9783527607495.
- "Maxair Autohaler (pirbuterol acetate inhalation aerosol) For Oral Inhalation Only. U.S. Full Prescribing Information". 3M Pharmaceuticals. Northridge, CA 91324. Retrieved 7 March 2016.
- Bianchi, Marina; Clavenna, Antonio; Bonati, Maurizio (2010). "Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period" (PDF). European Journal of Clinical Pharmacology. 66 (9): 929–936. doi:10.1007/s00228-010-0845-y. ISSN 0031-6970.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|